Main Uses of Siliq

Siliq (brodalumab) is a prescription medication used to treat a specific chronic skin condition known as moderate-to-severe plaque psoriasis. It is intended for adults who are candidates for systemic therapy (treatment that affects the entire body) or phototherapy (light treatment).

This medication is typically reserved for patients who have not responded to other systemic treatments or whose conditions have stopped responding to those therapies.

Plaque Psoriasis

Plaque psoriasis is an autoimmune condition where the immune system sends faulty signals that speed up the growth cycle of skin cells. This results in the formation of thick, red, scaly patches known as plaques. These patches can be itchy, painful, and may crack or bleed. Siliq works by targeting and blocking the interleukin-17 (IL-17) receptor, a protein involved in the inflammatory process that leads to these skin symptoms.

Expected Benefits

The primary goal of treatment with Siliq is to reduce the physical symptoms of plaque psoriasis and improve the overall condition of the skin.

• Skin Clearance: Many patients experience a significant reduction in the size and thickness of psoriasis plaques. In clinical observations, a high percentage of individuals achieve clear or almost clear skin.
• Reduction in Redness and Scaling: By inhibiting the inflammatory pathways, the medication helps to decrease the intense redness and the accumulation of silver-white scales characteristic of the condition.
• Symptom Relief: Treatment often leads to a decrease in the physical discomfort associated with plaques, such as persistent itching and soreness.
• Rapid Response: Some individuals may notice an improvement in their skin symptoms within the first few weeks of starting the medication, though full results typically take longer to manifest.

Siliq (brodalumab) is officially approved for use only in adults aged 18 years and older; its safety and effectiveness have not been established in pediatric patients.

Populations for Whom Use is Prohibited (Contraindications)

Population Category	Official Status
Crohn's Disease	Use is contraindicated (may cause worsening of the disease).
Active Tuberculosis (TB) Infection	Use is contraindicated (TB evaluation is mandatory prior to treatment).
Hypersensitivity	Use is contraindicated (known, clinically significant hypersensitivity to brodalumab or excipients).

Mandatory Restrictions and Limitations

Siliq is available only through a restricted program (e.g., REMS) due to reports of suicidal ideation and behavior. Prescribers must evaluate patients with a history of depression or suicidality.

Before treatment begins, patients must be screened for TB infection; if results show latent TB, treatment for TB must be initiated first. Patients must avoid concurrent use of live vaccines while receiving Siliq. The drug's risk status is unknown during pregnancy and breastfeeding due to a lack of human data; use requires a careful consideration of the risks versus benefits.

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Siliq (Brodalumab) primarily through two key domains: a strict restriction against certain co-administered products and the potential for pharmacokinetic changes with other medicines.

---

Contraindicated Combinations and Restrictions

Co-administration with Live Vaccines is a formally contraindicated combination and must be avoided. This restriction is based on the official pharmacodynamic risk of infection and the lack of data on the ability of the vaccine to generate a proper immune response while receiving Siliq. Additionally, the safety and efficacy of Siliq in combination with other Immunosuppressants or Biologics have not been evaluated in controlled studies, and this combination is restricted from documented use.

---

Pharmacokinetic and Metabolic Interactions

Siliq has the potential to influence the metabolism of other co-administered medicines by normalizing the activity of CYP450 enzymes, which are often suppressed during active chronic inflammation. This enzyme normalization can alter the systemic exposure of other drugs. Consequently, co-administration of Narrow Therapeutic Index Drugs that are CYP450 substrates requires monitoring when Siliq is initiated or discontinued. For example, clinical studies documented that the exposure (AUC) of the CYP3A4/3A5 substrate Midazolam increased by 24% after a single dose of Brodalumab.

---

Timing and Population Notes

The mandatory restriction for Live Vaccines constitutes a timing-based rule to avoid concurrent use. Furthermore, regulatory notes advise on discussing the timing of live vaccinations for infants who experienced third-trimester maternal exposure, as the drug is a known IgG2 antibody.

Target: IL-17 Receptor A Blockade

Siliq (brodalumab) is a fully human monoclonal antibody that acts as a highly selective receptor antagonist. Its primary action is to bind directly to the Interleukin-17 Receptor A ( IL-17RA) . This action physically blocks the receptor and prevents the entire IL-17 cytokine family (including IL-17A and IL-17F) from attaching and initiating the signal cascade.

---

Modulating the T H17 Signaling Cascade

The drug acts within biological systems characterized by heightened T H17-driven signaling. By halting the IL-17 signal, Siliq suppresses the entire downstream cascade, leading to the inhibition of pro-inflammatory mediator release and a reduction in immune cell infiltration and modulation of epithelial cell mitotic activity.

---

Resulting Physiological Effect

The consequence of this targeted pathway interference is the reduction of inflammatory signaling and modulation of epithelial cell proliferation. This mechanism contributes to modulating overactive signaling within the pathway, which influences the resulting physiological adjustments in tissue structure. This systemic reduction of IL-17-driven cellular activity results in a modulation of tissue morphology.

How to Use Siliq (Brodalumab): Official Administration Instructions

Siliq (brodalumab) is administered as a subcutaneous injection only. The official instructions for use are highly structured and are provided to patients under the guidance and supervision of a healthcare professional, as Siliq is available through a restricted distribution program.

Dosing and Schedule

The dosage of Siliq is 210 mg per injection, delivered through a prefilled syringe. Administration follows a strict two-phase schedule:

Phase	Dosing Frequency	Injection Amount
Induction	Weeks 0, 1, and 2	210 mg
Maintenance	Every 2 weeks thereafter	210 mg

Preparation and Procedure

Prior to injection, the prefilled syringe must be allowed to warm naturally to room temperature for approximately 30 minutes; it should not be warmed by any other method. The solution must be visually inspected and should appear clear to slightly opalescent and colorless to slightly yellow. Do not proceed if the solution is cloudy, discolored, or contains foreign particles.

Siliq must be injected into a suitable area of the skin, avoiding any sites that are tender, bruised, red, hard, thick, scaly, or affected by psoriasis. The injection is performed subcutaneously, and the full contents of the 1.5 mL syringe must be administered. Siliq is indicated only for use in adult patients (18 years of age and older). Consistent adherence to the administration schedule is required to meet the goals outlined in the official protocol.

Research Evidence / Overview of Studies

Phase 3 Trials: Efficacy and Quality of Life

Clinical trials are designed to investigate the potential effects of a drug. The available evidence includes findings from multi-center, randomized, placebo-controlled, double-blind Phase 3 trials.

Research explored the administration of the drug in relation to the frequency and severity of migraine attacks in adult participants.

• Mechanism of Action: Studies documented the suspected biochemical pathway related to the drug's action.
• Patient-Reported Outcomes: Researchers documented participant reports regarding quality of life and functionality. These studies assessed changes in the number of headache days recorded by participants.
• Medication Use: Research also investigated whether the drug use correlated with a change in the use of acute pain medication.

---

Long-Term Administration and Safety

Studies investigated the long-term administration and documented the safety profile over several years.

Pharmacokinetics and Drug-Drug Interactions

Research documented observations regarding cognitive function when the combination was administered concurrently with certain common treatments.

Safety Profile

Long-term administration of the drug was included in research protocols, including in participants with chronic migraines. Studies documented observed safety events related to long-term administration.

• Placebo Comparison: The primary Phase 3 trial included a placebo arm, documenting findings for the drug versus placebo regarding the frequency of migraine attacks.
• Liver Function: Studies evaluated the need to monitor liver enzyme levels in participants during long-term administration.

Common questions about Siliq (FAQ)

Q: How is Siliq generally described in comparison to other systemic psoriasis treatments?

Siliq is classified as an Interleukin-17 Receptor A ( IL-17RA) antagonist, which means it targets the receptor used by multiple inflammatory messengers. This targeted action involves binding and blocking the receptor. Official information indicates that the drug is approved for use in adults who have failed to respond or have lost response to other systemic therapies.

Q: How soon might patients see results (onset)?

Studies and official information indicate that the maximal effect of the drug was typically achieved by Week 12 in clinical trials. While some results may be observed earlier, there is a limited probability of becoming a responder after Week 16 of treatment.

Q: What might happen to psoriasis symptoms if Siliq treatment is discontinued?

Official product information contains guidance on stopping treatment if a patient does not respond adequately. Consideration should be given to discontinuing therapy if an adequate response is not achieved after 12 to 16 weeks of treatment, as continuing treatment beyond this point is considered unlikely to result in greater success.

Q: What is the Siliq REMS program, and what is its purpose?

The Siliq REMS program is a Risk Evaluation and Mitigation Strategy (REMS) program. It is a restricted distribution program required by the U.S. Food and Drug Administration (FDA) to help ensure that the potential benefits of the drug outweigh the risk of suicidal ideation and behavior.

Q: What are the known risks of suicidal thoughts or behavior associated with Siliq?

Suicidal ideation and behavior, including completed suicides, occurred in subjects treated with Siliq in clinical trials; however, the official labeling notes that a causal association between treatment with Siliq and an increased risk of these events has not been established.

Q: How are the risks and benefits of Siliq weighed for patients with a history of depression or mental health issues?

Official safety constraints require prescribers to evaluate patients before prescribing Siliq. Prescribers are advised to weigh the potential risks and benefits before using Siliq in patients with a history of depression or suicidality.

Q: What specific mood or behavior changes should a patient or caregiver watch for during treatment?

The official label requires patients and caregivers to seek medical attention for manifestations of suicidal ideation or behavior, new onset or worsening depression, anxiety, or other mood changes.

Q: What are the most commonly reported side effects in clinical trials?

According to the official product information, common adverse reactions (occurring in 1% of patients) reported in clinical trials include joint pain (arthralgia), headache, fatigue, diarrhea, and reactions at the injection site.

Q: Can Siliq cause a low white blood cell count (neutropenia)?

Studies and official information indicate that a decrease in the white blood cell count, known as neutropenia, has been reported as a common adverse reaction in some clinical trials.

Q: How is Siliq eliminated or cleared from the body?

Siliq is a monoclonal antibody (IgG2), a type of biologic medicine. It is primarily cleared from the body through the same metabolic processes that eliminate other naturally occurring IgG proteins.

Q: Does Siliq affect the results of blood tests, such as white blood cell count?

Siliq has been associated with a physiological change in the body that results in neutropenia, a decrease in the white blood cell count. This change is listed as a common adverse reaction in some clinical trials.

Q: Are patients who are older (geriatric) prescribed Siliq differently than younger adults?

Regulatory documents indicate that no specific dose adjustment is officially recommended for patients 65 years of age and older. However, data regarding the use of the drug in this specific population remains limited.

Q: What is the guidance regarding alcohol consumption while using Siliq?

Official regulatory documents do not contain specific information or guidance regarding the effects of alcohol consumption while using Siliq.

Q: Is it possible for Siliq to worsen existing eczema or cause an eczema-like rash?

Official regulatory documents include a warning that Siliq has been associated with severe skin reactions, including eczematous eruptions. These reactions can occur at any point, from days to months after the first dose.

Q: What are the common symptoms of fungal infections that can occur with Siliq use?

Clinical trials reported fungal infections as a potential adverse reaction, including tinea infections (such as ringworm) and Candida infections. Official guidance indicates that these types of events require medical evaluation.

Q: What is known about the use of Siliq in women who are pregnant or planning to conceive?

Official information states that there are limited data on the use of Siliq in pregnant women. Official product information states that women of childbearing potential are required to use effective contraception during treatment and for at least 12 weeks after the last dose.

Q: Are patients with a history of recurrent infections considered for Siliq therapy?

Prescribers are required to evaluate patients for infections before treatment. Official regulatory documents advise prescribers to consider the potential risks and benefits before initiating Siliq in patients with a chronic infection or a history of recurrent infection.

Q: What is the typical timeframe for a patient to allow the syringe to reach room temperature before injection?

The official administration instructions state that the prefilled syringe must be allowed to warm naturally to room temperature before injection. The typical timeframe given is approximately 30 minutes.

How to Store and Dispose of Siliq?

Siliq (brodalumab) prefilled syringes must be stored under controlled conditions to maintain product stability and safety. The syringes must be kept in the refrigerator, between 2°C and 8°C (36°F and 46°F).

Storage and Handling Rules

• Do not freeze and do not shake the syringe.
• Keep Siliq in its original carton to protect it from light.
• If the syringe is stored at room temperature (up to 25°C or 77°F), it must be used within 14 days and cannot be returned to the refrigerator.
• Keep all medicines out of the sight and reach of children.

Disposal Requirements

Used Siliq prefilled syringes are considered medical sharps. Immediately dispose of the used syringe in an FDA-cleared sharps disposal container. Do not place the syringe in household trash or dispose of it via wastewater. Follow state and local laws for the proper disposal of the full sharps container.